Rep. Robert Bresnahan, Jr. Sells Off Shares of Incyte Co. (NASDAQ:INCY)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Incyte Co. NASDAQ: INCY. In a filing disclosed on May 31st, the Representative disclosed that they had sold between $1,001 and $15,000 in Incyte stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
• Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
• Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
• Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.

Incyte Stock Up 0.5%

INCY traded up $0.31 during trading on Wednesday, reaching $67.42. The company had a trading volume of 1,577,488 shares, compared to its average volume of 2,275,351. Incyte Co. has a 12 month low of $53.56 and a 12 month high of $83.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. The business's fifty day moving average price is $61.01 and its 200 day moving average price is $67.28. The company has a market cap of $13.05 billion, a P/E ratio of 249.71, a PEG ratio of 0.41 and a beta of 0.68.

Incyte (NASDAQ:INCY - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.15. Incyte had a net margin of 0.77% and a return on equity of 0.05%. The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $996.17 million. During the same period last year, the business posted $0.64 earnings per share. The firm's quarterly revenue was up 19.5% on a year-over-year basis. Equities analysts anticipate that Incyte Co. will post 4.86 EPS for the current year.

Insiders Place Their Bets

In other Incyte news, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction on Friday, March 14th. The shares were sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the completion of the transaction, the executive vice president now directly owns 33,567 shares of the company's stock, valued at $2,272,150.23. The trade was a 37.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 17.80% of the company's stock.

Hedge Funds Weigh In On Incyte

Institutional investors have recently added to or reduced their stakes in the company. Quintet Private Bank Europe S.A. bought a new position in Incyte during the fourth quarter worth $26,000. Global X Japan Co. Ltd. boosted its position in Incyte by 144.7% during the fourth quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 230 shares during the period. R Squared Ltd bought a new position in Incyte during the fourth quarter worth $30,000. Banque Transatlantique SA bought a new position in Incyte during the first quarter worth $26,000. Finally, Raiffeisen Bank International AG bought a new position in Incyte during the fourth quarter worth $34,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on INCY. Morgan Stanley dropped their price objective on shares of Incyte from $69.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, March 24th. JMP Securities reiterated a "market perform" rating on shares of Incyte in a report on Tuesday, February 11th. Wall Street Zen upgraded shares of Incyte from a "buy" rating to a "strong-buy" rating in a report on Wednesday, April 30th. Stifel Nicolaus lifted their price objective on shares of Incyte from $75.00 to $77.00 and gave the company a "hold" rating in a report on Monday, February 10th. Finally, Guggenheim downgraded shares of Incyte from a "buy" rating to a "neutral" rating and set a $92.00 price objective on the stock. in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $72.53.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.